AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
299.58B
Market cap299.58B
Price-Earnings ratio
28.50
Price-Earnings ratio28.50
Dividend yield
1.69%
Dividend yield1.69%
Average volume
2.63M
Average volume2.63M
High today
$200.34
High today$200.34
Low today
$198.10
Low today$198.10
Open price
$194.19
Open price$194.19
Volume
18.39K
Volume18.39K
52 Week high
$200.34
52 Week high$200.34
52 Week low
$122.48
52 Week low$122.48

Stock Snapshot

AstraZeneca(AZN) stock is priced at $200.34, giving the company a market capitalization of 299.58B. It carries a P/E multiple of 28.50 and pays a dividend yield of 1.7%.

On 2026-02-11, AstraZeneca(AZN) stock traded between a low of $198.10 and a high of $200.34. Shares are currently priced at $200.34, which is +1.1% above the low and 0.0% below the high.

AstraZeneca(AZN) shares are trading with a volume of 18.39K, against a daily average of 2.63M.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $200.34 and a 52-week low of $122.48.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $200.34 and a 52-week low of $122.48.

AZN News

TipRanks 13h
AstraZeneca Earnings Call Highlights Growth And Pipeline

AstraZeneca plc ((GB:AZN)) has held its Q4 earnings call. Read on for the main highlights of the call. Valentine's Day Sale - 70% Off Unlock hedge fund-level da...

Benzinga 20h
AstraZeneca Cancer Portfolio Dominates Sales With Massive Double Digit Growth

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported fourth-quarter 2025 sales of $15.50 billion, up 4% year over year (+2% at constant currency or cc), almost in l...

AstraZeneca Cancer Portfolio Dominates Sales With Massive Double Digit Growth
Investor's Business Daily 23h
AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter Beat

Technology AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter Beat Licensing AstraZeneca (AZN) stock creeped higher early Tuesday after the pharma gi...

AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter Beat

Analyst ratings

83%

of 30 ratings
Buy
83.3%
Hold
3.3%
Sell
13.3%

More AZN News

TipRanks 1d
AstraZeneca reports Q4 core EPS $2.12, down 2% at CER

Reports Q4 revenue $14.54B, consensus $14.53B. Pascal Soriot, CEO, AstraZeneca (AZN), commenting on the results said: “In 2025 we saw strong commercial performa...

The Wall Street Journal 1d
AstraZeneca Forecasts Continued Growth on Pipeline Strength

Chief Executive Officer Pascal Soriot said AstraZeneca's pipeline momentum will continue into 2026. Dado Ruvic/Reuters AstraZeneca AZN -1.53 %decrease; red dow...

AstraZeneca Forecasts Continued Growth on Pipeline Strength
MarketWatch 1d
AstraZeneca profit climbs on cancer and heart drug demand

AstraZeneca on Tuesday announced fourth-quarter profit in line with expectations on demand for its cancer and heart drugs. The pharmaceutical company AZN UK:AZ...

AstraZeneca profit climbs on cancer and heart drug demand
Reuters 1d
Drugmaker AstraZeneca forecasts sales and profit growth in 2026 - Reuters

...

Drugmaker AstraZeneca forecasts sales and profit growth in 2026 - Reuters
TipRanks 5d
AstraZeneca’s TAPER Study Targets Simpler Severe Asthma Care With Tezepelumab

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is running a Phase 3b trial called TAPER (official title:...

TipRanks 5d
AstraZeneca’s Ondexxya Real-World Bleeding Study Update: What Investors Should Watch

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tool...

TipRanks 6d
AstraZeneca Targets Rare Bone Disorder Data in Russia, Laying Groundwork for Future HPP Opportunities

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is sponsoring an observational study titled “The Effect of...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.